Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Electroconvulsive therapy

9 evidence topics · 10 sources

CANMAT guideline: efficacy, course, and cognitive effects of ECT

“ECT remains one of the most effective treatment options for patients with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“ECT has demonstrated evidence of efficacy and tolerability in the treatment of depressive episodes, with response rates ranging from 65% to 75%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An acute course of ECT usually requires 6 to 12 sessions, with no difference in response outcomes between sessions given twice or thrice weekly” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Adverse effects on cognition are of most concern, although modern ECT techniques, including unilateral electrode placement and refined electrical dosing, have reduced both the incidence and severity of cognitive side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Nevertheless, some patients report significant and distressing gaps in autobiographical memory long after ECT, and the discrepancy between cognitive performance and subjective memory dysfunction remains controversial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although ECT has high response rates during acute treatment, recurrence occurs in 60% to 80% of patients at 6-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote